JPRN-jRCT1080221719未知4 期
An open-label, randomized, Phase IIIb trial evaluating the efficacy and safety of standard of care +/- continuous R435(bevacizumab) treatment beyond progression of disease (PD) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after first (1st)-line treatment with bevacizumab plus a platinum doublet-containing chemotherapy
试验速览
- 阶段
- 4 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Age >= 18 years.
- •-Ability to comply with the protocol.
- •-Histologically or cytologically confirmed non-squamous NSCLC
- •-At least 1 unidimensionally measurable lesion meeting RECIST (v.1.1) criteria.
- •-Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2.
排除标准
- •-Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component.
- •-EGFR-mutation-positive disease according to local laboratory testing.
研究者
相似试验
进行中（未招募）
1 期
A phase IIIb trial for evaluating the efficacy and safety of standard treatment, with or without bevacizumab, in patients with advanced non-squamous non-small cell lung cancer (NSCLC) who progressed after first (1st)-line treatment with bevacizumab plus a platinum doublet-containing chemotherapy.EUCTR2010-022645-14-ITF. Hoffmann-La Roche Ltd600
进行中（未招募）
1 期
A study to assess the efficacy and safety of standard of care with /without continuous bevacizumab treatment beyond progression of disease in patients with advanced lung cancer.ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)MedDRA version: 17.1Level: LLTClassification code 10066490Term: Progression of non-small cell lung cancerSystem Organ Class: 100000004864EUCTR2010-022645-14-ATF. Hoffmann-La Roche Ltd500
进行中（未招募）
1 期
An open-label, randomized, Phase IIIb trial evaluating the efficacy and safety of standard of care +/- continuous bevacizumab treatment beyond progression of disease (PD) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after first (1st)-line treatment with bevacizumab plus a platinum doublet-containing chemotherapy. Ensayo clínico de fase IIIb abierto, randomizado, para evaluar la eficacia y la seguridad del tratamiento estándar +/- tratamiento de mantenimiento con bevacizumab en pacientes con cáncer de pulmón no microcítico no escamoso (NSCLC) avanzado que han experimentado progresión de la enfermedad (PE) tras tratamiento de primera (1ª) línea con bevacizumab en combinación con un régimen de quimioterapia que contenía un doble compuesto de platino. - TML PulmóADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)Tratamiento de pacientes con NSCLC no escamoso, localmente recurrente o metastásico, que han experimentado progresión de la enfermedad tras recibir tratamiento de 1ª línea con bevacizumab más un régimen de quimioterapia que contenía un doble compuesto de platino y tratamiento de mantenimiento con bevacizumab (en monoterapia)MedDRA version: 12.1Level: LLTClassification code 10066490Term: Progression of non-small cell lung cancerEUCTR2010-022645-14-ESF. Hoffmann-La Roche Ltd600
进行中（未招募）
1 期
A study to assess the efficacy and safety of standard of care with / without continuous bevacizumab treatment beyond progression of disease in patients with advanced lung cancer.ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10066490Term: Progression of non-small cell lung cancerSystem Organ Class: 100000015833EUCTR2010-022645-14-DEF. Hoffmann-La Roche Ltd500
进行中（未招募）
1 期
An open-label, randomized, Phase IIIb trial evaluating the efficacy and safety of standard of care +/- continuous bevacizumab treatment beyond progression of disease (PD) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after first (1st)-line treatment with bevacizumab plus a platinum doublet-containing chemotherapyADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)MedDRA version: 12.1Level: LLTClassification code 10066490Term: Progression of non-small cell lung cancerEUCTR2010-022645-14-FRF. Hoffmann-La Roche Ltd600